Shire and FDA Agree on Study Proposal to Confirm Midrodrine Benefit

Shire plc

, announces that it has reached an agreement with the Center for Drug Evaluation and Research at the U.S. Food and Drug Administrationto conduct additional clinical trials to confirm the clinical benefit of ProAmatine, a medicine approved in 1996 under Subpart H for the treatment of symptomatic orthostatic hypotension.